SpyGlass Pharma, Inc. (SGP)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
SpyGlass Pharma, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| IM Ilko Menkov Vestal Point Capita LLP | 666,760 | $17.28M | $12.72M | -$4.56M | -26.4% |
SpyGlass Pharma, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| YC Yi Chen HC Wainwright & Co. | 29,916.03 | $689,879.39 | $566,908.78 | -$122,970.61 | -17.82% |
SpyGlass Pharma, Inc. (SGP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has SpyGlass Pharma, Inc. ever had a stock split?
SpyGlass Pharma, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Patrick H. Mooney CEO | NASDAQ (NMS) Exchange | 85220G109 CUSIP |
| US Country | 1,489 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company focused on creating innovative treatments for patients with chronic eye conditions. Founded in January 2019 by industry experts Malik Y. Kahook and Glenn Sussman, the company is headquartered in Aliso Viejo, California. SpyGlass Pharma aims to enhance the standard of care for individuals suffering from debilitating eye conditions through the development of advanced therapies and products.
Products and Services
- Bimatoprost Drug Pad-IOL System (BIM-IOL System)
This is the lead product candidate of SpyGlass Pharma, designed to be implanted during conventional cataract surgery. The BIM-IOL System aims to effectively reduce elevated intraocular pressure (IOP) in patients diagnosed with either open-angle glaucoma (OAG) or ocular hypertension (OHT). By providing a targeted therapeutic approach, this product seeks to improve the quality of life for individuals managing these chronic conditions.
